Heart Disease Clinical Trials in Nashville

Showing 161-180 of 496 trials

A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)

NCT06097663

This Phase 2a clinical trial will evaluate the effectiveness, safety, and tolerability of increasing dose strengths of an oral daily medication, DFV890, administered for 12 weeks, or a single s.c. dose of MAS825, to reduce key markers of inflammation related to CVD risk, such as IL-6 and IL-18, in approximately 28 people with known coronary heart disease and TET2 or DNMT3A CHIP (VAF ≥2%).

Coronary Heart DiseaseClonal Hematopoiesis of Indeterminate Potential (CHIP)

Novartis Pharmaceuticals31 participantsStarted Feb 2024

St Louis, Missouri, United States • Nashville, Tennessee, United States • Montreal, Quebec, Canada +3 more locations

TERMINATEDPhase 4< 1 mile

Metabolic Effects of Natriuretic Peptide Hormones

NCT03397966

Accumulating evidence suggests that the natriuretic peptide (NP) hormonal system has important effects on metabolism. However, more information is needed to better understand the effects of NPs on metabolism in humans. Therefore, the investigators propose a study to determine the effects of b-type natriuretic peptide (BNP) on energy and fat metabolism in humans. The investigators' primary hypothesis is that the administration of BNP will increase energy expenditure in humans. The investigators' secondary hypothesis is that BNP administration will promote changes in gene expression in fat tissue suggestive of fat "beiging" in humans. Interventions that safely increase energy expenditure and promote fat "beiging" represent potential strategies for treating metabolic dysfunction due to obesity.

ObesityCardiovascular Physiological PhenomenaMetabolism

VA Office of Research and Development5 participantsStarted Jul 2018

Nashville, Tennessee, United States • Nashville, Tennessee, United States

A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)

Metabolic Effects of Natriuretic Peptide Hormones

Heart Disease Trials in Other Cities

REmodeling the Left Ventricle With Atrial Modulated Pacing

ILUMIEN IV: OPTIMAL Percutaneous Coronary Intervention (PCI)

Reducing Sedentary Time in Patients With Cardiovascular Disease

Caffeine's Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)

Multicenter Automatic Defibrillator Implantation Trial With Subcutaneous Implantable Cardioverter Defibrillator

Physiologic Pacing Registry

Artificial Intelligence Mobile Health Trial Of A Digital Platform To Optimize GDMT Using Wearable Sensors

Utility of Donor-Derived Cell Free DNA in Association With Gene Expression Profiling

Breethe Abiomed Recovery RegisTry (BART)

Training in Exercise Activities and Motion for Growth (TEAM 4 Growth) RCT

Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy

Dapagliflozin at Discharge on Hospital Heart Failure Readmission

Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF

Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C Reduction

Exploratory Ph 2A, Double-Blind, Placebo-Controlled Dose Escalation Study of Safety, Tolerability, PD, & PK of HU6 for Subjects With Obese HFpEF

Acorai Machine Learning Generalization (MLG) Study

Cardiac Resynchronization Therapy Delivery Guided Non-Invasive Electrical and Venous Anatomy Assessment

Ammonia N-13 Myocardial Blood Flow Absolute Quantification by PET in Patients With Known or Suspected CAD (Ammonia MAP)

Other Conditions in Nashville